Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24O2 |
Molecular Weight | 296.4034 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4
InChI
InChIKey=BFPYWIDHMRZLRN-SLHNCBLASA-N
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
Molecular Formula | C20H24O2 |
Molecular Weight | 296.4034 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00977Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html
Sources: http://www.drugbank.ca/drugs/DB00977
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/ethinyl-estradiol-levonorgestrel.html
Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent. Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). Used for treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00977 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | LESSINA-21 Approved UseIndicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Launch Date1.016496E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
122.8 pg/mL |
0.06 mg single, oral dose: 0.06 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1335.8 pg × h/mL |
0.06 mg single, oral dose: 0.06 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.5 h |
0.06 mg single, oral dose: 0.06 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETHINYL ESTRADIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: Page: p.209 |
healthy, 14-54 n = 172 Health Status: healthy Condition: Pregnancy prevention Age Group: 14-54 Sex: F Population Size: 172 Sources: Page: p.209 |
Other AEs: Nausea... |
5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: Page: p.209 |
healthy, 14-54 n = 222 Health Status: healthy Condition: Pregnancy prevention Age Group: 14-54 Sex: F Population Size: 222 Sources: Page: p.209 |
Other AEs: Vomiting... |
5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: Page: p.211 |
healthy, 14-54 n = 222 Health Status: healthy Condition: Pregnancy prevention Age Group: 14-54 Sex: F Population Size: 222 Sources: Page: p.211 |
Other AEs: Mastalgia... |
0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Disc. AE: Dysfunctional uterine bleeding, Uterine bleeding... AEs leading to discontinuation/dose reduction: Dysfunctional uterine bleeding Sources: Page: p.4Uterine bleeding Headache Mood change Nausea Acne Weight gain |
0.595 mg single, oral Overdose Dose: 0.595 mg Route: oral Route: single Dose: 0.595 mg Co-administed with:: cyproterone acetate, p.o(34 mg, single) Sources: |
healthy, 29 n = 1 Health Status: healthy Age Group: 29 Sex: F Population Size: 1 Sources: |
Disc. AE: Pulmonary embolism... AEs leading to discontinuation/dose reduction: Pulmonary embolism Sources: |
0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.1 |
healthy Health Status: healthy Condition: Pregnancy prevention Sources: Page: p.1 |
Disc. AE: Thromboembolic event, Hepatic disease... AEs leading to discontinuation/dose reduction: Thromboembolic event Sources: Page: p.1Hepatic disease Headache Hypertension Uterine bleeding |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 48% | 5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: Page: p.209 |
healthy, 14-54 n = 172 Health Status: healthy Condition: Pregnancy prevention Age Group: 14-54 Sex: F Population Size: 172 Sources: Page: p.209 |
Vomiting | 23% | 5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: Page: p.209 |
healthy, 14-54 n = 222 Health Status: healthy Condition: Pregnancy prevention Age Group: 14-54 Sex: F Population Size: 222 Sources: Page: p.209 |
Mastalgia | 32% | 5 mg 1 times / day multiple, oral Highest studied dose Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: Page: p.211 |
healthy, 14-54 n = 222 Health Status: healthy Condition: Pregnancy prevention Age Group: 14-54 Sex: F Population Size: 222 Sources: Page: p.211 |
Acne | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Dysfunctional uterine bleeding | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Headache | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Mood change | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Nausea | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Uterine bleeding | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Weight gain | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.4 |
healthy, 18-41 n = 2185 Health Status: healthy Condition: Pregnancy prevention Age Group: 18-41 Sex: F Population Size: 2185 Sources: Page: p.4 |
Pulmonary embolism | Disc. AE | 0.595 mg single, oral Overdose Dose: 0.595 mg Route: oral Route: single Dose: 0.595 mg Co-administed with:: cyproterone acetate, p.o(34 mg, single) Sources: |
healthy, 29 n = 1 Health Status: healthy Age Group: 29 Sex: F Population Size: 1 Sources: |
Headache | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.1 |
healthy Health Status: healthy Condition: Pregnancy prevention Sources: Page: p.1 |
Hepatic disease | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.1 |
healthy Health Status: healthy Condition: Pregnancy prevention Sources: Page: p.1 |
Hypertension | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.1 |
healthy Health Status: healthy Condition: Pregnancy prevention Sources: Page: p.1 |
Thromboembolic event | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.1 |
healthy Health Status: healthy Condition: Pregnancy prevention Sources: Page: p.1 |
Uterine bleeding | Disc. AE | 0.02 mg 1 times / day multiple, oral Recommended Dose: 0.02 mg, 1 times / day Route: oral Route: multiple Dose: 0.02 mg, 1 times / day Co-administed with:: levonorgestrel, p.o(0.1 mg; q.d) Sources: Page: p.1 |
healthy Health Status: healthy Condition: Pregnancy prevention Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 1.5 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 14 uM] | yes (co-administration study) Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 15 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 19 uM] | yes (co-administration study) Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 2.1 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 2.8 uM] | yes (co-administration study) Comment: No Preincubation; see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 24 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 3.3 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 8.3 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 9.2 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19454483/ Page: 4.0 |
yes [IC50 9.2 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ Page: 12.0 |
yes | weak (co-administration study) Comment: ~22% increase in clerance of nicotine Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ Page: 12.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ |
yes | yes (co-administration study) Comment: Coadministration with propranolol: ~70% increase in glucuronidation; Coadministration with lamotrigine: ~64% increase in glucuronidation Sources: https://pubmed.ncbi.nlm.nih.gov/17253885/ |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
major | yes (co-administration study) Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI |
|||
minor | ||||
minor | ||||
minor | ||||
yes | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: see https://pubmed.ncbi.nlm.nih.gov/17253885/ for list of DDI |
PubMed
Title | Date | PubMed |
---|---|---|
A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. | 2000 Dec |
|
Method for non-invasively recording electrocardiograms in conscious mice. | 2001 |
|
Biphasic versus monophasic oral contraceptives for contraception. | 2001 |
|
Low dose of ethinyl estradiol can reverse the antiestrogenic effects of clomiphene citrate on endometrium. | 2001 |
|
Synthetic estrogens-mediated activation of JNK intracellular signaling molecule. | 2001 Apr |
|
Low dosage monophasic oral contraceptive use and intermittent exercise performance and metabolism in humans. | 2001 Apr |
|
High metabolization of catecholestrogens by type 1 estrogen sulfotransferase (hEST1). | 2001 Apr |
|
Oestrogens and oestrogenic activity in raw and treated water in Severn Trent Water. | 2001 Apr |
|
Effect of epomediol on ethinyloestradiol-induced changes in bile acid and cholesterol metabolism in rats. | 2001 Aug |
|
Regulation of sex hormone-binding globulin secretion in human hepatoma G2 cells. | 2001 Aug |
|
Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study. | 2001 Feb |
|
Metabolism of chylomicron cholesterol is delayed by estrogen. An in vivo study in the rat. | 2001 Feb |
|
Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol. | 2001 Feb |
|
[Comparison of 2 therapeutic strategies for severe endometriosis, in young women counsulting for sterility or pain. Results in cases of chronic pelvic pain]. | 2001 Feb |
|
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. | 2001 Feb |
|
Oestrogen replacement in young women with Turner's syndrome. | 2001 Feb |
|
Influence of low-dose oral contraceptives, alcohol, and grapefruit on. | 2001 Jan |
|
Anatomical and histological changes in the oviducts of Japanese quail, Coturnix japonica, after embryonic exposure to ethynyloestradiol. | 2001 Jan |
|
Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol. | 2001 Jan |
|
Comparative assessment of endocrine modulators with oestrogenic activity: I. Definition of a hygiene-based margin of safety (HBMOS) for xeno-oestrogens against the background of European developments. | 2001 Jan |
|
Preventive effects of a Chinese herbal medicine, hochu-ekki-to, on bone loss in ovariectomized rats. | 2001 Jan-Feb |
|
Development and validation of a homologous zebrafish (Danio rerio Hamilton-Buchanan) vitellogenin enzyme-linked immunosorbent assay (ELISA) and its application for studies on estrogenic chemicals. | 2001 Jul |
|
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. | 2001 Jul |
|
Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. | 2001 Jul |
|
Ovarian and endometrial function during hormonal contraception. | 2001 Jul |
|
Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. | 2001 Jul |
|
Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells. | 2001 Jul 30 |
|
A scheme of combined oral contraceptives for women more than 40 years old. | 2001 Jul-Aug |
|
Pubertal disorders in inv dup(15) syndrome. | 2001 Jun |
|
Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over. | 2001 Jun |
|
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. | 2001 Jun |
|
Determination of estrogens in river water by gas chromatography-negative-ion chemical-ionization mass spectrometry. | 2001 Jun 15 |
|
Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. | 2001 Mar |
|
Applicability of micellar electrokinetic chromatography to the analysis of estrogens in water. | 2001 Mar |
|
Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. | 2001 Mar |
|
Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse. | 2001 Mar |
|
Effects of estrogens in vitro and in vivo on cartilage growth in the tilapia (Oreochromis mossambicus). | 2001 Mar |
|
Induction of gene expression in sheepshead minnows (Cyprinodon variegatus) treated with 17beta-estradiol, diethylstilbestrol, or ethinylestradiol: the use of mRNA fingerprints as an indicator of gene regulation. | 2001 Mar |
|
Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. | 2001 Mar |
|
The emerging use of the 20-microg oral contraceptive. | 2001 Mar |
|
Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. | 2001 Mar |
|
Exposure of Chironomus riparius larvae to 17alpha-ethynylestradiol: effects on survival and mouthpart deformities. | 2001 Mar 26 |
|
Breast cancer and HRT--what are the data? | 2001 Mar-Apr |
|
Testosterone 5alpha-reductase inhibitory active constituents from Anemarrhenae Rhizoma. | 2001 May |
|
Streamlined beta-galactosidase assay for analysis of recombinant yeast response to estrogens. | 2001 May |
|
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. | 2001 May |
|
Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol. | 2001 May |
|
Neonatal exposure to potent and environmental oestrogens and abnormalities of the male reproductive system in the rat: evidence for importance of the androgen-oestrogen balance and assessment of the relevance to man. | 2001 May-Jun |
|
Effects of binary mixtures of six xenobiotics on hormone concentrations and morphometric endpoints of northern bobwhite quail (Colinus virginianus). | 2001 May-Jun |
|
Comparison of the antiatherosclerotic effect of tibolone with that of estradiol and ethinyl estradiol in cholesterol-fed, ovariectomized rabbits. | 2001 Summer |
Sample Use Guides
Usual Adult Dose for Endometriosis
Ethinyl estradiol-levonorgestrel products are packaged in 21 or 28 day dosage preparations. The last seven tablets in 28 day dosage preparations are hormonally inert.
Regardless of the number of tablets in a package, the cycle length for oral contraceptives is generally considered to be 28 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10837011
EE (=3 uM) completely inhibited TGF-beta-induced apoptosis in cut rat liver slices and hepatocytes
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:50:16 UTC 2022
by
admin
on
Fri Dec 16 16:50:16 UTC 2022
|
Record UNII |
423D2T571U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QG03AA06
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
NDF-RT |
N0000000100
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.1 (ETH/LEV)
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB03
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA02
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB05
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA07
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA13
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB07
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA10
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB01
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03CA01
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA07
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QL02AA03
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
NDF-RT |
N0000175825
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA03
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA15
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA04
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.3.1 (ETH/NOR)
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB01
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
NCI_THESAURUS |
C478
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA12
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA16
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA12
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA05
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA08
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA04
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03CA01
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB04
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB06
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA05
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA01
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA09
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA06
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA10
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB03
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA02
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
FDA ORPHAN DRUG |
28788
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA08
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB05
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB07
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
LIVERTOX |
382
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB04
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA11
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA13
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA16
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA15
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA03
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA09
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB02
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AA01
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AB06
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
EVRA (AUTHORIZED: CONTRACEPTION)
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-VATC |
QG03AA11
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
G03AB02
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
||
|
WHO-ATC |
L02AA03
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07277MIG
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
423D2T571U
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
423D2T571U
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
5991
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
1260001
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
C486
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
ETHINYL ESTRADIOL
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | Description: A white to slightly yellowish white, crystalline powder; odourless.Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS; soluble in acetone R and dioxan R.Category: Estrogen.Storage: Ethinylestradiol should be kept in a well-closed container, protected from light.Additional information: Ethinylestradiol may exist in 2 polymorphic forms one of which melts at about 183?C, the other, metastable, at about 143?C.RequirementsDefinition: Ethinylestradiol contains not less than 97.0% and not more than 102.0% of C20H24O2, calculated with reference to the dried substance. | ||
|
4903
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
10973
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
CHEMBL691
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
DB00977
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
M5058
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | Merck Index | ||
|
D004997
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
Ethinyl Estradiol
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
DTXSID5020576
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
200-342-2
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
4124
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | RxNorm | ||
|
437
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
7071
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
1082
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
57-63-6
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
3587
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY | |||
|
ETHINYL ESTRADIOL
Created by
admin on Fri Dec 16 16:50:16 UTC 2022 , Edited by admin on Fri Dec 16 16:50:16 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
DERIVATIVE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |